The immunohistochemistry on human breast cancer samples and the in silico analysis demonstrated that reduced expression of HPGD was associated with worse patient outcomes, consistent with a study demonstrating that low levels of HPGD predicted reduced recurrence free survival and OS in a cohort of breast cancer patients, split into normal weight, overweight and obese groups, in which few received endocrine therapy (15%) [41]. Here, HPGD is linked to breast cancer.